Support Group Calender
Jackson Clarion-Ledger - Alzheimer’s Disease-Dementia Support Group, 6:30 p.m., activity room, Trace Pointe Assisted Living Facility, Clinton, free, details, (601) 926-1188 WEDNESDAY Caregivers Support Group, 10 a.m., St. Dominic/Jackson Memorial Hospital, 969 Lakeland Drive
Piedmont Profile: Her strength, others’ generosity powered Jasmine
Winston-Salem Journal - Glenn had little contact with her mother in recent years, and her father suffered from Alzheimer’s disease before dying this past spring. Glenn said that she had no choice but to get out on her own at such a young age. She first lived with a cousin
AXONYX Inc. Announces Second Quarter 2006 Financial Results
Genetic Engineering News - Axonyx currently has three compounds in development for Alzheimer’s disease, namely Phenserine - a potential symptomatic and disease progression treatment of mild to moderate Alzheimer’s disease (AD), Posiphen(TM) - a potential disease progression
Walk-off death has spotlight on home
Charlotte.com - A 59-year-old man suffering from Alzheimer’s who disappeared from a Cleveland County adult-care home for a week was found dead behind the facility that cared for him. The body of Kelly “Buck” Whitesides was found Saturday in a wooded area about 844
Alzheimer’s Drug May Have Other Uses
KFMB - WASHINGTON — A medicine used to treat patients with Alzheimer’s Disease may point the way to better care in cases of poisoning by nerve agents and pesticides. Galantamine, a medication approved for treatment of mild to moderate Alzheimer’s
Chronic Diseases are Leading Causes of Death among Senior Citizens
Senior Journal - Increase in Alzheimer’s and Renal Diseases Alzheimer s disease and renal diseases (including nephritis, nephritic syndrome, and nephrosis) have gained importance as causes of death among older persons over the past two decades. Alzheimer s
Evotec Successfully Completes Phase I for Potential Alzheimer s
WebWire - 8 August 2006, Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, Evotec ) today announced the successful completion of Phase I with EVT 101, an NR2B subtype-specific NMDA receptor antagonist for the treatment